Danish pharmaceutical giant Novo Nordisk has chosen the UAE for a new regional distribution centre that will become one of just three global hubs the company uses to manage worldwide product distribution (per local reports).
Scale of the hub
The UAE facility is planned to serve up to 70 countries across the Gulf, Africa and Central Asia through successive operational phases, supporting access to treatment for more than 2.6 million patients across a population base exceeding one billion people. The decision was announced on May 22, 2026 and welcomed by the Emirates Drug Establishment (EDE), the federal regulator for pharmaceuticals (per Zawya / EDE).
Why the UAE
Novo Nordisk said the choice followed benchmarking studies that highlighted the UAE's leadership in managing pharmaceutical ecosystems and its ability to integrate regulation, manufacturing, logistics and data within a single operational framework. The company also cited the country's advanced investment and logistics capabilities and its stable business environment as drivers of the decision (per local reports).
What Novo Nordisk makes
The Danish firm is best known globally for diabetes treatments including insulin therapies and for the GLP-1 class of drugs that includes Ozempic, used for type 2 diabetes, and Wegovy, used for chronic weight management. The new UAE hub will handle the regional supply of these and other Novo Nordisk products, shortening lead times for healthcare systems across the wider region (per Arabian Business).
Beyond logistics
The company also announced plans to open a scientific office in the UAE and to roll out a talent development programme aimed at training Emirati nationals for roles in the pharmaceutical sector. EDE described the package of commitments as evidence that the UAE is becoming a strategic supply-chain anchor rather than only an end market (per Zawya).
Wider context
The deal lands alongside a sequence of pharma investments in the UAE in 2026, as federal and emirate-level authorities pitch the country as a base for regional manufacturing and distribution. For Novo Nordisk, having only three global distribution centres makes the UAE selection a meaningful elevation of the country's position in the company's global supply network, joining a small group of hubs that route products to dozens of countries from a single base.
